Background Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent adverse eff ects related to concentration, which can cause treatment interruption. We aimed to ascertain whether adverse eff ects could be reduced with either a shorter modifi ed acetylcysteine schedule, antiemetic pretreatment, or both.
Introduction
Overdose of paracetamol (acetaminophen) is common, and the drug is the most frequent cause of acute liver failure in Europe and North America.
1,2 During 2011-12, more than 38 000 admissions for paracetamol poisoning were recorded in England 3 and, in 2011, at least 137 000 enquiries were made to US poisons centres about paracetamol exposure. 4 The toxic mechanisms of paracetamol-understood for more than 40 years-enabled development of a specifi c antidote, acetylcysteine, in the 1970s. [5] [6] [7] Intravenous regimens 5 are now in widespread use, with between 18 000 and 40 000 treatment courses administered in the UK annually. 8 However, these regimens have never under gone formal dose-ranging studies. 9 In particular, little attention has been paid to the initial dose regimen, which might cause dose-related vomiting in up to 60% of patients and anaphylactoid reactions leading to treatment interruption and refusal in a further 20%. [10] [11] [12] The acetylcysteine regimen, although slightly variable worldwide, is universally complex; it includes three, separate, weight-related infusions over diff erent timeframes, with a resultant high risk of medication error. [13] [14] [15] Until September, 2012, the standard regimen for acetylcysteine used in the UK delivered 50% of the total dose over the fi rst 15 min, rather than over a period of 1 h as with the US dosing schedule (panel 1). 16 Although a higher frequency of dose-related adverse reactions might be expected with this faster infusion rate, no diff erences have been noted between these two initial doses. 17 The total duration of the infusion is between 20·25 h and 21 h for these regimens.
We postulated that the incidence of adverse eff ects reported with acetylcysteine treatment could be reduced with a simpler regimen that delivers the same total dose but over a shorter (12 h ) period and with a lower, slower initial infusion dose (panel 1). 16 Monte Carlo modelling based on published data from patients indicates that acetylcysteine concentrations at 20·25 h would be similar with the two regimens. 18, 19 Therefore, we did a factorial study to compare the rates of adverse reactions-with and without antiemetic pretreatment-between the standard acetylcysteine protocol and a shorter (12 h) modifi ed schedule.
Methods

Participants
The study methods have been reported in full elsewhere. 19 In summary, we did a double-blind, randomised controlled trial at three acute clinical units in the UK, initially at the Royal Infi rmary in Edinburgh and the Royal Victoria Infi rmary, Newcastle, and subsequently at Aberdeen Royal Infi rmary, to ensure adequate recruitment within the funding timeframe. Recruitment started on Sept 6, 2010, and ended on Dec 31, 2012. Patients were eligible for the study if they presented after an acute paracetamol overdose and needed treatment with acetylcysteine, on the basis of standard UK guidance for management. 16, 19 Exclusion criteria are shown in fi gure 1 and described elsewhere. 19 We obtained ethics and regulatory approval for the study. Trained clinician recruiters obtained informed consent from all patients before trial entry.
Procedures
We treated patients who presented within 8 h of paracetamol ingestion on the basis of their measured paracetamol concentration in plasma. Individuals who presented more than 8 h after ingestion were managed initially according to the history of the ingested dose, but subsequently we withdrew them from the study if measured concentrations of paracetamol in plasma were below standard UK treatment lines (200 mg/L or 100 mg/L at 4 h, depending on risk assessment). When clinically indicated, we administered further doses of acetylcysteine after completion of the initial schedule, according to standard UK practice. 16 We pretreated all patients with either intravenous ondansetron (4 mg) or a matched placebo (saline), then we administered either the UK standard acetylcysteine regimen or the shorter (12 h) version (panel 1). 16 We recorded adverse events in the patient's clinical record and extracted data to the case report form. We also noted the use and timing of rescue drugs; we used intravenous cyclizine as antiemetic rescue and, initially, intravenous chlorphenamine for anaphylactoid symptoms. We allowed use of other treatments when clinically indicated, and we recorded these in the clinical record. The research team gathered outcome and survival data via the electronic system at every hospital and clinical notes, and they recorded this information in the case report form. We also obtained data from a sample of patients to assess acetylcysteine concentrations in the two regimens, and these will be reported separately.
We made two major protocol amendments. First, we extended the time allowed for ingestion of paracetamol from 1 h to 2 h to assist recruitment, because in practice many patients were found to ingest large single overdoses over a period up to 2 h. Second, after new UK guidance was issued in September, 2012, 19, 20 we used the 100 mg/L paracetamol nomogram line for recruitment of all patients. We established a data monitoring committee that met about every 6 months; they were aware of and supported all protocol modifi cations and made no other changes to the study.
Randomisation and masking
We used a 2×2 factorial trial design, which included four parallel groups: ondansetron pretreatment and the shorter acetylcysteine regimen (ondansetron-modifi ed); ondansetron and the standard schedule (ondansetronstandard); placebo and the shorter acetylcysteine protocol (placebo-modifi ed); and placebo and the standard regimen (placebo-standard). We did randomisation by minimisation to achieve balance (1:1:1:1 allocation), according to the following prognostic factors: reported paracetamol dose (<16 g or ≥16 g); risk factors for paracetamol-induced hepatic toxic eff ects; and time to presentation (<8 h or ≥8 h). 16 We used an online program for the randomisation, which was provided by the Edinburgh Clinical Trials Unit, thus ensuring allocation concealment. To achieve masking, ondansetron and saline placebo ampoules were identical in appearance, but because of ethical and practical concerns, we could not mask the administering team to the acetylcysteine regimen. Patients allocated to the shorter modifi ed acetylcysteine regimen received intravenous 5% dextrose after the full acetylcysteine dose was given, to ensure the total infusion time was the same in both groups. 
Outcome measures
The primary outcome, defi ned a priori, was the proportion of patients who did not vomit or retch and did not need rescue antiemetic drugs-as assessed by clinical case records and patients' self-reporting-within 2 h of initiation of acetylcysteine. 19 For clarity, this outcome measure is reported in terms of treatment benefi t (ie, symptom presence, need to treat, or both).
We assessed secondary outcomes up to 12 h after the start of treatment. Secondary outcomes were: the proportion of patients without nausea (Likert scale <5 of 11), vomiting, or retching up to 12 h after initiation of acetylcysteine treatment (for clarity, expressed as treatment benefi t); and occurrence of anaphylactoid reactions, which was judged by the need for treatment or acetylcysteine interruption for an anaphylactoid response, by self-reported fl ushing, itchy skin, skin rash, chest pain, breathlessness, wheeze, and tongue or lip swelling (all assessed on Likert scales, >4 of 11), and by recorded changes in blood pressure (fall of systolic >20 mm Hg) and pulse rate (rise of >20 bpm). We categorised the severity of anaphylactoid reactions on a predefi ned threegrade severity scale. 19, 21 Grade 1 reactions (mild) were defi ned either as a positive response in one of the domains on the Likert scales or as a change in blood pressure or pulse rate (as described). Grade 2 reactions (moderate) fulfi lled either two or more positive symptom domains on the Likert scales, cardio vascular changes (blood pressure or pulse), or both, but with no requirement for specifi c treatment or stopping acetylcysteine treatment. Grade 3 reactions (severe) included patients who either had acetyl cysteine treatment interrupted, an intervention with an anti-allergy drug, or both.
We prespecifi ed other analyses to assess the frequency of hepatic toxic eff ects at the end of treatment (derived from case records), including a greater than 50% increase (17), detained under the Mental Health Act (15), permanent cognitive impairment (9), pregnant (6), on anticoagulants (5); non-English speaking (4), unable to complete questionnaires (3), and history of hypersensitivity to serotonin antagonists (3). in alanine aminotransferase activity over the admission value and activity of alanine aminotransferase greater than 1000 IU/L. We also recorded, at 20·25 h after initiation of acetylcysteine, when the international normalised ratio rose to more than 1·3, although this measurement can potentially be confounded by acetylcysteine. 11, 22 Finally, in a subset of Edinburgh patients, we did a post-hoc analysis of microRNA miR-122, which is a sensitive and specifi c marker of hepatic injury. 23, 24 Statistical analysis To achieve at least 80% power to detect a relative risk of 0·6 for the proportion of patients with vomiting within 2 h (from 60% in the placebo group to 36% in the treated group), we needed to enrol 91 patients on ondansetron and 91 on placebo (p=0·025). This number was increased to allow for dropouts and to ensure we included 50 patients in each of the four groups in the factorial study. 19 To account for the factorial design, we used a signifi cance level of 2·5%, and we calculated 97·5% CIs. All applicable statistical tests were two-sided. The analysis was done according to randomised treatment group, irrespective of adherence to treatment (intention to treat). Because of the trial design and the need to recruit late-presenting patients before data for paracetamol concentration were available, we subsequently excluded some individuals (fi gure 1); data collection and follow-up were stopped after treatment discontinuation for any reason. If patients had missing data for an outcome variable, we removed them from formal statistical analysis at that timepoint.
We analysed binary variables (including the primary outcome) with logistic regression, adjusting for prognostic factors included in the minimisation algorithm and for centre. Because we did a factorial trial, we entered the main eff ect for both treatment comparisons into the model concurrently. We derived Kaplan-Meier plots for use of antiemetic or anaphylactic rescue medication from the start of the fi rst infusion, by regimen and treatment. We analysed grade of anaphylaxis with proportional odds logistic regression. We also did sensitivity analyses, unadjusted analyses, and analyses adjusting for the interaction between treatment groups, but none of these aff ected the conclusions. For the microRNA analysis, we did two-way analysis of variance on log-transformed data. This trial is registered with the European Clinical Trials Database (EudraCT number 2009-017800-10) and ClinicalTrials.gov (identifi er NCT01050270).
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all study data and the corresponding author had respon sibility for the decision to submit for publication.
Results
Between Sept 6, 2010, and Dec 31, 2012, 3311 patients presented with paracetamol overdose and were screened for inclusion in the study; 1539 were judged potentially suitable for acetylcysteine treatment, 369 were eligible for inclusion, and 222 underwent randomisation (fi gure 1). Table 1 shows the number of patients at each participating centre and their baseline demographic features, according to treatment allocation. Groups were well balanced at baseline with respect to age, sex, weight, ingested paracetamol dose, paracetamol nomogram band, other risk factors for paracetamol hepatic toxic eff ects, and other ingested agents (including opiates and antihistamines) or regular prescribed drugs. Of 19 patients who withdrew from the study before completion of treatment (fi gure 1), 14 were below treatment lines and fi ve refused to complete the study. No emergency unmasking took place. Table 2 presents available outcome data for patients who had vomiting or retching or used rescue medication within 2 h of acetylcysteine initiation. This primary outcome was signifi cantly less frequent in patients who received the shorter modifi ed acetylcysteine regimen compared with those allocated to the standard schedule (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0·0001) and in those treated with ondansetron versus placebo (0·41, 0·20-0·80; p=0·003). No interaction was noted between the two treatment comparisons (p=0·69).
The secondary outcome of nausea (Likert >4 of 11), vomiting, or retching up to 12 h after the start of treatment was less common in patients who received the shorter modifi ed acetylcysteine regimen compared with those who were allocated the standard protocol (adjusted odds ratio 0·37, 97·5% CI 0·18-0·79; p=0·003). Similarly, the treatment diff erence was signifi cant for those pretreated with ondansetron versus individuals who received placebo (0·35, 0·17-0·74; p=0·002). The KaplanMeier plot for time to antiemetic rescue is shown in fi gure 2.
Anaphylactoid symptoms were recorded in 133 (64%) of 208 patients overall, and these were classifi ed as mild in 79 (38%), moderate in 18 (9%), and severe in 36 (17%). Anaphylactoid symptoms were absent in 50 (46%) of 108 patients allocated to the shorter modifi ed acetylcysteine regimen and 25 (25%) of 100 who received the standard treatment. Fewer patients allocated to the shorter modifi ed acetylcysteine regimen had clinically relevant grade 3 (severe) reactions needing either drug treatment or interruption of the acetylcysteine infusion (fi ve of 108, fi ve treated, two interrupted) compared with those assigned to the standard regimen (31 of 100, 31 treated, 26 interrupted; adjusted common odds ratio A 50% increase in activity of alanine amino transferase 20·25 h after initiation of the acetylcysteine infusion was recorded in 22 (11%) of 201 patients, 13 who were allocated to the standard acetyl cysteine regimen and nine of those assigned to the shorter modifi ed schedule (adjusted odds ratio 0·60, 97·5% CI 0·20-1·83). This escalation in activity of alanine amino trans ferase was more frequent in patients pre treated with ondansetron (16 of 100) compared with those receiving placebo (six of 101; 3·30, 1·01-10·72; p=0·024; appendix p 1). An increased frequency in the doubling of alanine amino transferase (post-hoc analysis) was noted in patients pretreated with ondansetron (14 of 100) compared with those given placebo (fi ve of 101; adjusted odds ratio 3·47, 97·5% CI 0·95-12·66; p=0·031). At the end of acetylcysteine infusion, fi ve of 202 patients had activity of alanine aminotransferase greater than 1000 IU/L (two ondansetron-modifi ed, one ondansetronstandard, two placebo-standard) and 25 of 201 people had an international normalised ratio higher than 1·3 (seven ondansetron-modifi ed, seven ondansetronstandard, two placebo-modifi ed, nine placebo-standard); no diff erence was recorded between treatment allocations (appendix p 1). Six (6%) patients allocated to the shorter modifi ed acetylcysteine regimen received additional acetyl cysteine infusions (post-hoc analysis) compared with 11 (10%) of those allocated to the standard schedule (adjusted odds ratio 0·46, 97·5% CI 0·13-1·68; p=0·180); 12 (11%) patients assigned to ondansetron pretreatment received additional infusions of acetylcysteine compared with fi ve (5%) of those who received placebo beforehand (2·82, 0·76-10·53; p=0·077). No patients developed acute kidney injury.
In a post-hoc analysis of miR-122 (normalised for hsa-let-7d-5p) in 124 patients from Edinburgh, no diff erence was apparent at the end of either of the acetylcysteine regimens (standard, median ΔΔCt 0·5 [IQR 0·2-3·4] vs modifi ed, ΔΔCt 1·1 [0·4-2·4]; p=0·79). However, miR-122 was higher in patients pretreated with ondansetron than those who received placebo (ΔΔCt 1·3 [0·4-3·4] vs ΔΔCt 0·6 [0·2-2·0]; p=0·03).
A total of 174 adverse events were reported by 170 participants across all groups. Most of these were expected reactions: 92 gastrointestinal and 13 hepatobiliary. One patient died, an elderly man, who recovered from paracetamol overdose but died 20 days after the end of treatment from previously diagnosed malignant disease.
Discussion
The fi ndings of our study show that a shorter (12 h) modifi ed acetylcysteine regimen substantially reduces the frequency of both vomiting and serious anaphylactoid reactions when compared with the standard schedule for acetylcysteine administration (duration 20·25 h). The shorter duration of acetylcysteine infusion off ers simpler administration, a probable reduction in administration errors, and a potential decrease in the length of the hospital stay. However, further clinical trials and studies of novel 23 and traditional 25 biomarkers are needed to confi rm the effi cacy and safety of the modifi ed regimen before widespread adoption into clinical practice.
Vomiting was reduced by pretreatment with ondansetron, thus increasing the antiemetic benefi t of the modifi ed regimen, but this fall was associated with an unexpected increase in activity of aminotransferase. Potential mechanisms include either alterations in paracetamol metabolism or glutathione synthesis or a direct eff ect of ondansetron on a stressed liver, although a type 1 error is possible. Although these eff ects did not seem to be clinically important, further research is needed before ondansetron is used routinely for this indication.
Our study fi ndings confi rm that symptomatic adverse eff ects, particularly vomiting and anaphylactoid reactions (panel 2), are associated commonly with the standard UK regimen for acetylcysteine administration. These events are unpleasant, result in treatment interruption and delay, and can cause patients to refuse or even be denied treatment in subsequent presentations. 1 Such eff ects can be severe, with 28 (13%) patients in our trial having their treatment interrupted. Anaphylactoid reactions occur most commonly at lower concentrations of paracetamol and, thus, are more likely to be seen in patients now treated under new UK guidance. 8, 12, 29, 30 Not all patients eligible for treatment with acetylcysteine were included in our study (fi gure 1), mostly because of a staggered overdose, alcohol intoxication, or drowsiness. These exclusions are unlikely to aff ect our main fi ndings. However, effi cacy and safety of the modifi ed acetylcysteine regimen in staggered overdoses will need to be assessed. Some patients who were included in our study initially were withdrawn later when paracetamol concentrations showed they did not need acetylcysteine. These individuals featured in the analysis if they were still receiving acetylcysteine at the time of primary outcome assessment. These factors are unlikely to aff ect the generalisability of our results.
In view of the complexity of the standard acetylcysteine regimen, a double-blind comparison with the shorter modifi ed protocol was not feasible. The potential regimens are complex, requiring either fi ve infusions in the standard procedure (for 15 min, 1 h 45 min, 2 h 15 min, 7 h 45 min, and 8 h 15 min) or two concurrent infusion regimens for every patient.
The open nature of the comparison might have led to observer bias in the assessment of adverse drug reactions. However, the primary outcome-the noted absence of vomiting, retching, and use of antiemetic rescue treatment-is objective, as is the measurement of concentrations of aminotransferases. Assessment of anaphylactoid reactions was made as objective as possible by use of a detailed scoring system, including patient self-rating at prespecifi ed times.
Although our trial is, to our knowledge, the largest randomised controlled trial of paracetamol poisoning ever undertaken, it was not suffi ciently powered to show non-inferiority of the modifi ed acetylcysteine regimen for prevention of hepatotoxic eff ects. We used a 50% increase in alanine aminotransferase concentration as a surrogate marker of liver damage, because more severe liver dysfunction is rare (although rises in the international normalised ratio and activity of alanine aminotransferase >1000 IU/L were also measured). Doubling of alanine aminotransferase and miR-122 fi ndings were similar for both acetylcysteine regimens, but both measurements were more frequently abnormal in patients administered ondansetron. We identifi ed a large proportion of patients with no change in the amount of alanine aminotransferase and with paracetamol concentrations less than 20 mg/L at 12 h (appendix p 1). We believe this patient group could be discharged early, if fi ndings of a larger study confi rm the absence of inferiority.
The shorter modifi ed acetylcysteine regimen caused signifi cantly less nausea, vomiting, and anaphylactoid reactions, with diminished requirement for rescue treatment. This approach off ers potentially major advantages for patients, staff , and health-care institutions. Further research in larger numbers of patients is needed to confi rm the effi cacy of the shorter acetylcysteine regimen.
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Panel 2: Research in context
Systematic review
We searched PubMed and the Cochrane Database for clinical trials and systematic reviews of acetylcysteine treatment for paracetamol overdose and antiemetic pretreatment published between January, 1975, and December, 2008, with the terms "paracetamol", "acetaminophen", "overdose", "acetylcysteine", and "anti-emetic". In 2006, the Cochrane Collaboration published a systematic review of evidence for management of paracetamol overdose. 26 The effi cacy of diff erent oral and intravenous acetylcysteine regimens did not diff er with respect to prevention of hepatotoxic eff ects but these drugs were associated with adverse events such as vomiting and anaphylactoid reactions. The conclusion stated that the best method of administration of acetylcysteine and the most benefi cial dose had not been reported. No published trials were identifi ed of antiemetic prophylaxis before administration of intravenous acetylcysteine treatment. Although high-dose metoclopramide was eff ective at prevention of emesis before oral acetylcysteine in one small study, 27 this drug was associated with a high incidence of extrapyramidal adverse eff ects in young adults, making it unsuitable for this patient group. For prophylaxis of nausea and vomiting in other settings (eg, postoperative), more trial evidence was available for effi cacy of ondansetron than for other antiemetics, in a Cochrane Collaboration systematic review. 28 Our search did not identify any studies that have addressed the need for treatment interruption because of adverse events.
Interpretation
We have shown in our study that a 12 h intravenous regimen of acetylcysteine, with an initial loading dose over 2 h, is eff ective at reducing the incidence of vomiting and anaphylactoid reactions, compared with the standard 20·25 h intravenous acetylcysteine schedule. Our trial was not powered to assess non-inferiority of the modifi ed protocol, but no diff erence in effi cacy was recorded between groups. Ondansetron pretreatment was eff ective at reducing vomiting but had no eff ect on anaphylactoid reactions and was associated with a rise in the amount of aminotransferase. Other key advantages of the 12 h regimen include simplicity and substantial reductions in the need to treat anaphylactoid reactions and to interrupt the acetylcysteine infusion because of adverse eff ects, both of which complicate and prolong hospital care. This shorter and simpler protocol, if proven to be non-inferior to the conventional acetylcysteine regimen, has considerable potential to reduce adverse eff ects and length of hospital stay in patients requiring acetylcysteine treatment after a paracetamol overdose.
